Hostname: page-component-7479d7b7d-fwgfc Total loading time: 0 Render date: 2024-07-12T20:56:33.411Z Has data issue: false hasContentIssue false

Bristol-Myers Squibb and the Medicines Patent Pool – An Unlikely Marriage?

Published online by Cambridge University Press:  20 January 2017

Rachel Chu*
Affiliation:
Pugatch ConsiliumandFaculty of Maastricht University

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Reports
Copyright
Copyright © Cambridge University Press 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Medicines Patent Pool, “MPP and Bristol-Myers Squibb Sign Agreement to Further Expand Access to a Key HIV Medicine”, 12 December 2013, http://www.medicinespatentpool.org/mpp-and-bristol-myers-squibb-sign-agreement-to-further-expand-access-to-a-key-hiv-medicine/.

2 As identified by the World Health Organization (WHO), Type II diseases refer to diseases for which 90% of cases occur in poor countries including HIV/AIDS, tuberculosis and malaria. Type III diseases comprise a range of tropical diseases including Buruli ulcer, Chagas disease and dengue. ( Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) (2006), Public health, innovation and intellectual property rights, WHO, Geneva, p.13 Google Scholar)

3 Wall Street Journal, “Bristol Settles Patent Dispute With Teva Over Reyataz HIV Drug, 27 October 2011, http://online.wsj.com/news/articles/SB10001424052970203554104577001490166083700.

4 World Intellectual Property Organization, Patent Landscape Report on Atazanavir, November 2011, http://www.wipo.int/export/sites/www/freepublications/en/patents/946/wipo_pub_946_2.pdf.

5 Medicines Patent Pool, “MPP and Bristol-Myers Squibb Sign Agreement…”

6 Ibid.

7 Ibid.

8 MPP website, “Licenses in the pool”, http://www.medicinespatentpool.org/licensing/current-licences/.

9 Yadav, P. (2010), Differential Pricing for Pharmaceuticals: Review of current knowledge, new findings and ideas for action, conducted for the UK Department for International Development, August 2010

10 Towse, A. (2013), “Does Price Discrimination Have a Place in Pharmaceutical Pricing in Developing Countries: Examples of Differential Pricing Schemes. Can We Move from Theory to Practice?”, Office of Health Economics, presented at the International Health Economics Association, 9th World Congress, Sydney, 7-10 July 2013, http://www.slideshare.net/OHENews/towse-price-discrimination-ihea-2013-v1.

11 Ibid.

12 Dyer, G., “Netherlands acts against re-sold Aids drugs Africa illegal re-exports uncovered”, The Financial Times, 3 October 2002

13 Alcorn, K. (2007), “Abbott announces Kaletra price cut for lower middle-income countries, makes new offer to Thailand”, AIDS map, 10 April 2007

14 WHO (2012), Draft global vaccine action plan, 65th WHA Provisional agenda item 13.12, p.4

15 BVGH/BIO, Biotechnology: Bringing Innovation to Neglecteed Disease Research and Development, p.5

16 Ibid.

17 WHO (2013), Sustaining the drive to overcome the global impact of neglected tropical diseases: Second WHO report on neglected tropical diseases, p.x; WHO (2012), Draft global vaccine …, p.7; Access to Medicine Foundation (2012), Access to Medicine Index, p.12

18 Ibid.

19 See, for example: DiMasi, J., Hansen, R. & Grabowski, H. (2003) “The Price of Innovation: New Estimates of Drug Development Costs”, Journal of Health Economics, Vol. 22, pp. 151185 CrossRefGoogle Scholar; and Tufts Center for the Study of Drug Development (2011),“Drug Developers Are Aggressively Changing the Way They Do R&D”, http://csdd.tufts.edu/news/complete_story/pr_outlook_2011; Congressional Budget Office (CBO) (2009), Research and Develompent in the Pharmaceutical Industry, p.21; Frank, R. (2003), “New Estimates of Drug Development Costs”, Journal of Health Economics, Vol.22, No.2, pp.107142 CrossRefGoogle ScholarPubMed; Paul, S., Mytelka, D., Dunwiddie, C., Persinger, C., Munos, B., Lindborg, S., et al (2010), “How to improve R&D productivity: the pharmaceutical industry's grand challenge”, Nature Reviews Drug Discovery, Vol.9, pp.203214 Google ScholarPubMed

20 Pedrique, B., Strub-Wourgaft, N., Olliaro, P., Trouiller, P., Ford, N., Some, C., Pecoul, B. & Bradol, J.H. (2013), “The drug and vaccine pipeline for neglected diseases, 2000-2011: a systematic assessment”, Forthcoming publication; Drugs for Neglected Diseases (DNDi) and Medicins Sans Frontieres (MSF) (2012), Medical Innovation for Neglected Patients, p.2 Google Scholar

21 Pugatch, M.P., Chu, R. & Torstensson, D. (2012), Assembling the pharmaceutical R&D puzzle for needs in the developing world: An assessment of new and proposed delinking initiatives aimed at encouraging R&D into neglected and tropical diseases and specific Type II diseases, Commissioned by IFPMA

22 GAVI Alliance, “Pneumococcal AMC”, http://www.gavialliance.org/funding/pneumococcal-amc/